How to Value a Home Healthcare Equipment Business in 2026

Home healthcare equipment businesses — sometimes called HME or DME suppliers — sit at the intersection of healthcare and logistics. You're managing inventory, delivery fleets, billing compliance, and patient relationships all at once. It's operationally complex, heavily regulated, and for those reasons, most generalist business brokers don't understand how to value them properly.

I've worked on enough DME transactions to know that the valuation framework is specific to this niche. The multiples are real, the buyer pool is active, and the industry tailwinds — aging population, hospital-at-home programs, Medicare policy shifts — are strong. But the details matter enormously.

The Baseline: 4-6x EBITDA for Well-Run Operations

Home healthcare equipment businesses with clean operations, proper accreditation, and diversified payer mix trade at 4-6x EBITDA. A business doing $3M in revenue with $500K EBITDA and solid fundamentals might sell for $2M-$3M. Companies with strong respiratory programs and high recurring rental revenue push toward the top of the range. Companies that are primarily retail/cash sales of mobility equipment sit at the bottom.

The range exists because "home healthcare equipment" encompasses several sub-segments with very different economics:

• Respiratory (oxygen concentrators, CPAP/BiPAP, ventilators): The premium segment. High recurring monthly rental revenue, strong Medicare reimbursement, and growing demand from an aging population. Respiratory-focused businesses trade at 5-6x EBITDA.
• Hospital beds and patient lifts: Steady rental revenue with long placement durations. Moderate margins. Trade at 4-5x.
• Mobility (wheelchairs, scooters, walkers): Mix of rental and retail sales. Complex billing for power wheelchairs. Medicare competitive bidding has compressed margins significantly. Trade at 3.5-5x.
• CPAP resupply: High-margin, recurring revenue stream. Patients need new masks, tubing, and filters every 3-6 months. Companies with strong resupply programs can command premium multiples — this is the closest thing to SaaS in the HME world.

The Recurring Revenue That Drives Premium Multiples

What separates a 4x business from a 6x business in HME is almost always the monthly rental patient count and resupply compliance rate.

Monthly rental patients are the core recurring revenue stream. A patient on home oxygen generates $200-$400/month in rental revenue for 36 months (the Medicare rental cap), then transitions to a lower maintenance payment. A CPAP patient generates $100-$250/month during the initial rental period. Every active rental patient is essentially an annuity, and buyers value them accordingly.

The key metric is your active rental patient census — how many patients are currently on rental equipment and generating monthly revenue. A business with 500 active rental patients generating $150K/month in rental revenue is worth significantly more than one with the same total revenue but derived primarily from one-time equipment sales.

Resupply compliance rate measures what percentage of eligible CPAP patients are actively receiving replacement supplies on schedule. The industry average is around 30-40%. Top operators hit 60-70%. The difference in revenue is massive — a company with 1,000 CPAP patients at 65% compliance generates $200K-$300K more annual revenue than the same patient base at 35% compliance. Buyers love high resupply compliance because it indicates both operational competence and patient engagement.

Payer Mix: The Make-or-Break Factor

Your payer mix directly determines your margins, your compliance risk, and ultimately your valuation.

Medicareis the largest payer for most HME companies (typically 40-60% of revenue). Medicare rates are set by CMS, subject to competitive bidding adjustments, and have been generally declining in real terms. Heavy Medicare dependence isn't inherently bad — the volume is there — but buyers will stress-test your profitability against further rate reductions.

Commercial insurancetypically pays 20-40% above Medicare rates. Companies with 30%+ commercial mix command premium valuations because the margins are better and the rates are negotiable. If you've built relationships with commercial payers and have favorable contracts, that's a genuine asset.

Medicaid pays the least and creates the most administrative burden. Companies with 30%+ Medicaid mix typically trade at the bottom of the range. The exception is states with relatively generous Medicaid rates and managed Medicaid programs that pay closer to commercial rates.

Cash/retailsales avoid payer complexity entirely but lack the predictability of insurance-funded rental revenue. A small cash component (10-15%) is fine. A business that's primarily cash retail is really a medical supply store, and the healthcare M&A buyer pool largely isn't interested.

Competitive Bidding Area Exposure

Medicare's Competitive Bidding Program has reshaped HME valuations more than any other single factor. If your service area falls within a competitive bidding area (CBA), your Medicare reimbursement rates for affected product categories are set by competitive bid, often 30-50% below standard fee schedule rates.

Buyers scrutinize this carefully. A business generating $2M in revenue in a non-CBA market is worth more than the same revenue in a CBA market because the non-CBA rates are higher and more stable. Companies operating primarily in rural or non-CBA markets have a structural advantage that translates directly to valuation.

If you operate in a CBA, the mitigation strategy is diversifying into product categories not subject to competitive bidding (complex rehab, certain respiratory categories) and building commercial payer volume where you can negotiate rates independently.

Accreditation and Compliance: Non-Negotiable

Every HME business must be accredited by an approved organization (ACHC, The Joint Commission, HQAA, or BOC) and enrolled with Medicare. This isn't optional — without accreditation, you can't bill Medicare or most commercial payers.

Buyers verify accreditation status, survey history, and compliance track record during diligence. A clean accreditation history with no adverse surveys is table stakes. Deficiencies, corrective action plans, or gaps in accreditation history will delay or kill a deal.

Surety bond and licensure requirements vary by state and are increasingly stringent. Make sure your state licenses, surety bonds, and business registrations are current. Letting these lapse creates a compliance gap that spooks buyers.

The Consolidation Opportunity

Lincare (owned by Linde), Rotech, AdaptHealth, and several PE-backed platforms are actively acquiring HME businesses. The industry is fragmented — thousands of small operators across the country — which creates textbook roll-up conditions.

Platform buyers typically pay 4-5x EBITDA for bolt-on acquisitions and 5-7x for platform-sized deals ($5M+ EBITDA). They look for geographic fill-in (coverage in markets where they have gaps), respiratory program strength, and high rental patient census. If you're in a market where a major platform has limited presence, you may have strategic value beyond your financial metrics.

The hospital-at-home trend is expanding the addressable market. Major health systems are partnering with HME providers to support patients recovering at home with equipment that would traditionally have been used in the hospital. Companies positioned as hospital-at-home equipment partners are attracting attention from both strategic and financial buyers.

Preparing for Sale

Build your rental patient census. Every new respiratory or CPAP patient you add is recurring revenue that directly increases your valuation. Invest in referral relationships with pulmonologists, sleep specialists, and hospital discharge planners.

Maximize resupply compliance.If you're at 35%, getting to 55%+ is achievable with automated outreach, text messaging, and a dedicated resupply coordinator. The revenue lift pays for itself within months and the valuation impact is substantial.

Clean up your billing. Ensure your claims have clean submission rates above 95%, denial rates below 10%, and timely filing compliance. Messy billing is the number one operational red flag in HME due diligence.

Maintain your fleet.Delivery vehicles and equipment in good condition signal a well-run operation. Deferred maintenance on your delivery fleet or rental equipment tells buyers they're inheriting a capital expenditure problem.

The Bottom Line

Home healthcare equipment businesses are valued on the strength of their recurring rental revenue, the quality of their payer mix, and their regulatory compliance posture. The industry is consolidating, the demographic tailwinds are strong, and the hospital-at-home movement is expanding the market. Companies with strong respiratory programs, high resupply compliance, and clean accreditation histories are attracting multiple offers in the current market. If you're 2-3 years from an exit, focus on building your rental patient census and diversifying your payer mix — those two levers will move your valuation more than anything else.